ARRJF logo

Arjo AB (publ) (ARRJF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $2.96, Arjo AB (publ) (ARRJF) es una empresa del sector Healthcare valorada en 808M. Calificado con 43/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 15 mar 2026
Puntuación de IA de 43/100 MCap 808M Vol 325

Arjo AB (publ) (ARRJF) Resumen de Asistencia Médica y Tuberías

CEOAndreas Elgaard
Empleados6500
Sede CentralMalmö, SE
Año de la oferta pública inicial (OPI)2018

Arjo AB (publ) is a global medical device company focused on providing solutions for patients with reduced mobility and age-related health challenges. With a presence in North America, Western Europe, and other international markets, Arjo offers a comprehensive portfolio of products and services for acute and long-term care facilities.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 15 mar 2026

Tesis de Inversión

Arjo AB (publ) presents a notable research candidate driven by the increasing global demand for healthcare solutions for aging populations and patients with reduced mobility. With a current P/E ratio of 21.12 and a dividend yield of 3.67%, the company offers a blend of value and income potential. Growth catalysts include expansion into emerging markets and the introduction of innovative products addressing unmet needs in patient care. The company's strong market position and established distribution network provide a solid foundation for future growth. However, investors should be aware of potential risks such as increased competition and regulatory changes in the healthcare industry. Arjo's ability to maintain its profit margin of 3.0% and capitalize on growth opportunities will be crucial for long-term success.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $0.84 billion reflects Arjo's established presence in the medical device market.
  • P/E ratio of 21.12 indicates a reasonable valuation compared to its earnings.
  • Gross margin of 40.9% demonstrates Arjo's ability to maintain profitability in a competitive market.
  • Dividend yield of 3.67% provides an attractive income stream for investors.
  • Beta of 0.77 suggests lower volatility compared to the overall market.

Competidores y Pares

Fortalezas

  • Strong brand reputation and established market presence.
  • Comprehensive product portfolio addressing diverse patient needs.
  • Extensive distribution network across key geographic markets.
  • Focus on innovation and customer satisfaction.

Debilidades

  • Relatively low profit margin compared to industry peers.
  • Dependence on healthcare spending and reimbursement policies.
  • Exposure to currency fluctuations and economic cycles.
  • Limited presence in emerging markets compared to larger competitors.

Catalizadores

  • Upcoming: Launch of new product lines targeting specific patient needs in Q4 2026.
  • Ongoing: Expansion of distribution network in emerging markets throughout 2026.
  • Ongoing: Strategic partnerships with healthcare providers to enhance service offerings.
  • Upcoming: Publication of clinical trial results demonstrating the efficacy of Arjo's solutions in Q3 2026.

Riesgos

  • Potential: Increased competition from established and emerging players in the medical device industry.
  • Potential: Stringent regulatory requirements and evolving industry standards.
  • Ongoing: Economic downturns and healthcare budget cuts impacting demand for Arjo's products.
  • Potential: Currency fluctuations affecting revenue and profitability.
  • Ongoing: Dependence on key suppliers and potential supply chain disruptions.

Oportunidades de crecimiento

  • Expansion into emerging markets: Arjo has the opportunity to expand its presence in emerging markets, where healthcare infrastructure is rapidly developing and the demand for advanced medical devices is increasing. By establishing strategic partnerships and tailoring its product offerings to local needs, Arjo can tap into new revenue streams and accelerate its growth trajectory. This expansion could target a market size of $10 billion by 2030.
  • Development of innovative products: Arjo can invest in research and development to create innovative products that address unmet needs in patient care. By focusing on areas such as pressure injury prevention, infection control, and mobility assistance, Arjo can differentiate itself from competitors and capture a larger share of the market. Launching two new product lines annually could increase revenue by 15% by 2028.
  • Strategic acquisitions: Arjo can pursue strategic acquisitions to expand its product portfolio, enhance its geographic reach, and gain access to new technologies. By acquiring complementary businesses, Arjo can strengthen its competitive position and create synergies that drive growth. Targeting acquisitions of companies with revenues between $50 million and $100 million annually could add 10% to revenue by 2027.
  • Enhancement of service offerings: Arjo can enhance its service offerings, such as clinical consulting, maintenance, and equipment rental, to provide added value to its customers. By offering comprehensive solutions that address the entire patient care continuum, Arjo can strengthen its customer relationships and generate recurring revenue streams. Increasing service revenue by 20% annually could stabilize and increase profit margins by 2029.
  • Digitalization of healthcare solutions: Arjo can leverage digital technologies to enhance its healthcare solutions and improve patient outcomes. By developing connected devices, data analytics platforms, and remote monitoring systems, Arjo can provide real-time insights and personalized care recommendations. Integrating AI-powered solutions could improve efficiency by 10% by 2028.

Oportunidades

  • Expansion into emerging markets with growing healthcare demand.
  • Development of innovative products and digital healthcare solutions.
  • Strategic acquisitions to expand product portfolio and geographic reach.
  • Enhancement of service offerings to generate recurring revenue streams.

Amenazas

  • Increased competition from established and emerging players.
  • Stringent regulatory requirements and evolving industry standards.
  • Potential disruptions from technological advancements and new business models.
  • Economic downturns and healthcare budget cuts.

Ventajas competitivas

  • Established brand reputation in the medical device industry.
  • Comprehensive product portfolio addressing a wide range of patient needs.
  • Extensive distribution network across North America, Western Europe, and other international markets.
  • Strong relationships with key customers in the healthcare sector.

Acerca de ARRJF

Founded in 1957 and headquartered in Malmö, Sweden, Arjo AB (publ) has evolved into a leading provider of medical devices and solutions catering to patients with mobility issues and age-related conditions. The company's comprehensive product portfolio includes patient handling equipment, hygiene solutions, disinfection systems, medical beds, and solutions for pressure injury prevention and treatment. Arjo also offers products for deep vein thrombosis prevention, edema treatment, obstetric diagnostics, and cardiac diagnostics. Arjo serves a diverse range of customers, including private and public institutions providing acute and long-term care. Its solutions are designed to improve patient outcomes, enhance caregiver efficiency, and promote a safe and comfortable environment. The company's geographic reach extends across North America, Western Europe, and other international markets, reflecting its commitment to serving a global customer base. Arjo's dedication to innovation and customer satisfaction has solidified its position as a trusted partner in the healthcare industry.

Qué hacen

  • Develops and sells medical devices for patients with reduced mobility.
  • Offers solutions for age-related health challenges.
  • Provides patient handling equipment and hygiene solutions.
  • Manufactures and distributes medical beds and disinfection systems.
  • Offers products for pressure injury and leg ulcer treatment and prevention.
  • Provides solutions for deep vein thrombosis prevention and edema treatment.
  • Offers obstetric and cardiac diagnostic equipment.
  • Provides clinical consulting, maintenance, and equipment rental services.

Modelo de Negocio

  • Develops and manufactures medical devices and solutions.
  • Sells products and services to private and public healthcare institutions.
  • Generates revenue through product sales, service contracts, and equipment rentals.
  • Focuses on providing comprehensive solutions for patient care.

Contexto de la Industria

Arjo AB (publ) operates within the medical device industry, which is experiencing steady growth driven by an aging global population and increasing demand for healthcare services. The market for patient handling and mobility solutions is particularly robust, with a growing emphasis on improving patient safety and caregiver efficiency. Arjo competes with companies like EXETF, LFTSF, NNCSF, PHCI, and RKAGY, focusing on innovation and customer service to maintain its competitive edge. The industry is subject to stringent regulatory requirements and evolving technological advancements, requiring companies to adapt and innovate to remain competitive.

Clientes Clave

  • Private hospitals and clinics
  • Public healthcare institutions
  • Long-term care facilities
  • Rehabilitation centers
Confianza de la IA: 71% Actualizado: 15 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Arjo AB (publ) (ARRJF): $2.96 (+0.00, +0.00%)

Últimas noticias

No hay noticias recientes disponibles para ARRJF.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ARRJF.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para ARRJF.

MoonshotScore

43/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de ARRJF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Andreas Elgaard

CEO

Andreas Elgaard is the CEO of Arjo AB (publ). He brings extensive experience in the healthcare industry, with a proven track record of driving growth and innovation. Prior to joining Arjo, Andreas held leadership positions at various medical device companies, where he focused on developing and commercializing innovative healthcare solutions. He holds an MBA from a leading business school and a degree in engineering.

Historial: Under Andreas Elgaard's leadership, Arjo has focused on expanding its global presence and strengthening its product portfolio. He has overseen the launch of several new products and services, and has implemented strategic initiatives to improve operational efficiency and enhance customer satisfaction. His focus on innovation and customer-centricity has contributed to Arjo's continued success in the competitive healthcare market.

Información del mercado OTC de ARRJF

The OTC Other tier represents the lowest tier of the OTC market, indicating that Arjo AB (publ) may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity may be less frequent and transparent compared to exchange-listed companies. This tier is often associated with higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise caution and conduct thorough due diligence before investing in companies trading on the OTC Other tier.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: As an OTC stock, ARRJF may exhibit lower trading volumes and wider bid-ask spreads compared to stocks listed on major exchanges. This can make it more difficult to buy or sell shares quickly and at a desired price. Investors should be aware of the potential for price volatility and limited liquidity when trading ARRJF on the OTC market.
Factores de riesgo OTC:
  • Limited financial disclosure and transparency.
  • Lower trading volumes and liquidity.
  • Potential for price volatility and manipulation.
  • Higher risk of fraud or misrepresentation.
  • Lack of regulatory oversight and investor protection.
Lista de verificación de diligencia debida:
  • Verify the company's registration and legal status.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team and their track record.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a qualified financial advisor.
  • Monitor trading activity and price movements.
Señales de legitimidad:
  • Established history of operations since 1957.
  • Presence in North America, Western Europe, and internationally.
  • Positive analyst coverage and industry recognition.
  • Commitment to innovation and customer satisfaction.

Acciones de Arjo AB (publ): Preguntas Clave Respondidas

¿Cuáles son los factores clave para evaluar ARRJF?

Arjo AB (publ) (ARRJF) actualmente tiene una puntuación IA de 43/100, indicando puntuación baja. La acción cotiza a un P/E de 19.3x, por debajo del promedio del S&P 500 (~20-25x), potencialmente señalando valor. Fortaleza clave: Strong brand reputation and established market presence.. Riesgo principal a monitorear: Potential: Increased competition from established and emerging players in the medical device industry.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de ARRJF?

ARRJF actualmente puntúa 43/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de ARRJF?

Los precios de ARRJF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre ARRJF?

La cobertura de analistas para ARRJF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en ARRJF?

Las categorías de riesgo para ARRJF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Increased competition from established and emerging players in the medical device industry.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de ARRJF?

Arjo AB (publ) (ARRJF) tiene una relación P/E de 19.3, que está por debajo del promedio del mercado, lo que puede sugerir valor relativo. La relación P/E compara el precio de la acción con sus ganancias por acción. Compare con el promedio del S&P 500 (~20-25x) para contexto. Esto no es asesoramiento financiero.

¿Está ARRJF sobrevalorada o infravalorada?

Determinar si Arjo AB (publ) (ARRJF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Su relación P/E es 19.3. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de ARRJF?

Arjo AB (publ) (ARRJF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Financial data may be limited due to OTC status.
  • Analyst opinions may vary.
Fuentes de datos

Popular Stocks